{"id":"aflibercept-ivt","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain or discomfort"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular inflammation"},{"rate":null,"effect":"Endophthalmitis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1742982","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Aflibercept functions as a soluble decoy receptor containing VEGF-binding domains from VEGFR1 and VEGFR2 fused to the Fc portion of human IgG1. By sequestering circulating VEGF and PlGF, it prevents their interaction with endogenous VEGF receptors on endothelial cells, thereby reducing abnormal blood vessel formation and leakage characteristic of retinal and choroidal diseases. The intravitreal formulation (IVT) delivers the drug directly to the eye for treatment of retinal pathologies.","oneSentence":"Aflibercept IVT is a vascular endothelial growth factor (VEGF) trap that binds and neutralizes VEGF and placental growth factor (PlGF) to inhibit pathological angiogenesis and vascular permeability.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:20:12.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Retinal diseases associated with pathological angiogenesis and vascular permeability (e.g., diabetic retinopathy, retinal vein occlusion, age-related macular degeneration)"}]},"trialDetails":[{"nctId":"NCT07496567","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-04-30","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT06864988","phase":"PHASE3","title":"4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-03-03","conditions":"Macular Neovascularization Secondary to Age-Related Macular Degeneration","enrollment":480},{"nctId":"NCT07489131","phase":"PHASE3","title":"Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"Alvotech Swiss AG","startDate":"2026-03","conditions":"Diabetic Macular Edema","enrollment":256},{"nctId":"NCT07482176","phase":"PHASE3","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)","status":"RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2026-03-16","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD","enrollment":284},{"nctId":"NCT07118670","phase":"PHASE4","title":"High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Wood, MD","startDate":"2025-12-08","conditions":"Proliferative Diabetic Retinopathy (PDR)","enrollment":40},{"nctId":"NCT06929143","phase":"","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-04-14","conditions":"Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)","enrollment":3000},{"nctId":"NCT07317934","phase":"PHASE3","title":"Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)","status":"RECRUITING","sponsor":"Innostellar Biotherapeutics Co.,Ltd","startDate":"2026-01-14","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD","enrollment":332},{"nctId":"NCT05705258","phase":"","title":"A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-03-27","conditions":"Retinopathy of Prematurity, Newborns, Infants","enrollment":75},{"nctId":"NCT06850922","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-06-22","conditions":"Diabetic Macular Edema","enrollment":546},{"nctId":"NCT07440225","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-03-31","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT05197270","phase":"PHASE1, PHASE2","title":"4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2021-12-09","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":215},{"nctId":"NCT06550011","phase":"PHASE1, PHASE2","title":"Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avirmax Biopharma Inc","startDate":"2024-08-07","conditions":"Neovascular (Wet) AMD","enrollment":18},{"nctId":"NCT07064759","phase":"PHASE3","title":"Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-07-22","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":480},{"nctId":"NCT07365371","phase":"PHASE4","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-01","conditions":"Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)","enrollment":174},{"nctId":"NCT05769153","phase":"PHASE1, PHASE2","title":"Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Alcon Research","startDate":"2023-12-06","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":140},{"nctId":"NCT06422507","phase":"PHASE3","title":"A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-05-29","conditions":"Diabetic Macular Edema","enrollment":333},{"nctId":"NCT05850520","phase":"PHASE3","title":"A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-05-15","conditions":"Macular Edema Secondary to Retinal Vein Occlusion","enrollment":892},{"nctId":"NCT04932980","phase":"NA","title":"Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Berner Augenklinik","startDate":"2022-05-09","conditions":"Wet Age-related Macular Degeneration","enrollment":80},{"nctId":"NCT06856577","phase":"PHASE3","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2025-02-28","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD","enrollment":284},{"nctId":"NCT04522167","phase":"PHASE3","title":"Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Bioeq GmbH","startDate":"2020-07-21","conditions":"Neovascular Age-related Macular Degeneration","enrollment":434},{"nctId":"NCT06116890","phase":"PHASE2","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-01-31","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":180},{"nctId":"NCT06116916","phase":"PHASE2","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-01-09","conditions":"Diabetic Macular Edema (DME)","enrollment":150},{"nctId":"NCT06769412","phase":"","title":"A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-07-01","conditions":"Retinal Vasculitis","enrollment":550000},{"nctId":"NCT06491914","phase":"PHASE3","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-24","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":1118},{"nctId":"NCT04015180","phase":"PHASE3","title":"Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-18","conditions":"Retinopathy of Prematurity (ROP)","enrollment":100},{"nctId":"NCT07105228","phase":"","title":"Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-07-15","conditions":"Retinal Vasculitis","enrollment":290000},{"nctId":"NCT05930561","phase":"PHASE2","title":"4D-150 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2023-08-09","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":72},{"nctId":"NCT04270747","phase":"PHASE3","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-06-22","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":576},{"nctId":"NCT04423718","phase":"PHASE3","title":"Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-11","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1011},{"nctId":"NCT05536973","phase":"PHASE2","title":"Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2022-08-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":69},{"nctId":"NCT04429503","phase":"PHASE2, PHASE3","title":"Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-06-29","conditions":"Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT06011798","phase":"PHASE2","title":"Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)","status":"COMPLETED","sponsor":"Unity Biotechnology, Inc.","startDate":"2023-08-23","conditions":"Diabetic Macular Edema, Retinal Disease, Macular Edema","enrollment":52},{"nctId":"NCT03622580","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-09-05","conditions":"Diabetic Macular Edema","enrollment":940},{"nctId":"NCT03622593","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-10-09","conditions":"Diabetic Macular Edema","enrollment":951},{"nctId":"NCT04418427","phase":"PHASE2","title":"ADVM-022 Intravitreal Gene Therapy for DME","status":"COMPLETED","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2020-05-28","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":36},{"nctId":"NCT05989126","phase":"PHASE3","title":"Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-15","conditions":"Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":35},{"nctId":"NCT06942520","phase":"PHASE2","title":"Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)","status":"RECRUITING","sponsor":"Sierra Eye Associates","startDate":"2025-03-18","conditions":"Diabetic Macular Edema","enrollment":18},{"nctId":"NCT05986786","phase":"PHASE3","title":"Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2024-02-28","conditions":"Chorioretinal Vascular Disease","enrollment":35},{"nctId":"NCT06470373","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"Rophibio, Inc.","startDate":"2025-07","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":434},{"nctId":"NCT05704725","phase":"PHASE3","title":"A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-01-23","conditions":"Chorioretinal Vascular Disease","enrollment":49},{"nctId":"NCT06817343","phase":"PHASE1","title":"A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)","status":"ENROLLING_BY_INVITATION","sponsor":"Exegenesis Bio","startDate":"2024-09-10","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":12},{"nctId":"NCT02434328","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-07-28","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1048},{"nctId":"NCT02307682","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-12-08","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1775},{"nctId":"NCT06708637","phase":"PHASE4","title":"Ocular Safety and Usability Study for FYB203 PFS","status":"COMPLETED","sponsor":"Formycon AG","startDate":"2024-09-20","conditions":"Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema","enrollment":30},{"nctId":"NCT05473715","phase":"PHASE4","title":"A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment","status":"TERMINATED","sponsor":"Bayer","startDate":"2023-04-25","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":3},{"nctId":"NCT05155293","phase":"PHASE3","title":"Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2022-06-28","conditions":"Neovascular (Wet) AMD","enrollment":413},{"nctId":"NCT03939767","phase":"","title":"Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-05-12","conditions":"Wet Age-related Macular Degeneration","enrollment":1563},{"nctId":"NCT04740905","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Macular Edema, Branch Retinal Vein Occlusion","enrollment":553},{"nctId":"NCT04740931","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion","enrollment":729},{"nctId":"NCT05403749","phase":"PHASE2","title":"A Study of Longer Interval of IVT IBI302 in Subjects With nAMD","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-06-29","conditions":"Neovascular Age-related Macular Degeneration","enrollment":132},{"nctId":"NCT04864834","phase":"PHASE3","title":"Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Sandoz","startDate":"2021-05-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":485},{"nctId":"NCT02305238","phase":"PHASE4","title":"Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-12-19","conditions":"Wet Macular Degeneration","enrollment":288},{"nctId":"NCT02924311","phase":"","title":"Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-21","conditions":"Diabetic Retinopathy","enrollment":402},{"nctId":"NCT04480463","phase":"PHASE3","title":"A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Sam Chun Dang Pharm. Co. Ltd.","startDate":"2020-08-13","conditions":"Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration","enrollment":576},{"nctId":"NCT05885503","phase":"PHASE3","title":"Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-06-08","conditions":"Diabetic Macular Edema","enrollment":316},{"nctId":"NCT04126317","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-11-04","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":106},{"nctId":"NCT03714308","phase":"","title":"Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-01-28","conditions":"Macular Degeneration","enrollment":554},{"nctId":"NCT04101721","phase":"PHASE3","title":"Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-10-30","conditions":"Retinopathy of Prematurity","enrollment":127},{"nctId":"NCT03290794","phase":"","title":"Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-02-14","conditions":"Wet Age-related Macular Degeneration","enrollment":100},{"nctId":"NCT05282004","phase":"PHASE3","title":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit","status":"COMPLETED","sponsor":"Sandoz","startDate":"2022-05-16","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":36},{"nctId":"NCT03710564","phase":"PHASE3","title":"Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-30","conditions":"Age-Related Macular Degeneration","enrollment":535},{"nctId":"NCT05161806","phase":"PHASE3","title":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe","status":"COMPLETED","sponsor":"Sandoz","startDate":"2022-03-11","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":30},{"nctId":"NCT04684394","phase":"PHASE2","title":"A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Gemini Therapeutics, Inc.","startDate":"2020-12-29","conditions":"Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration","enrollment":50},{"nctId":"NCT04004208","phase":"PHASE3","title":"Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-09-25","conditions":"Retinopathy of Prematurity (ROP)","enrollment":113},{"nctId":"NCT05345236","phase":"PHASE3","title":"A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-08-19","conditions":"Wet Age-related Macular Degeneration","enrollment":366},{"nctId":"NCT02348359","phase":"PHASE2","title":"X-82 to Treat Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Tyrogenex","startDate":"2015-03-16","conditions":"Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration","enrollment":157},{"nctId":"NCT03953079","phase":"PHASE2","title":"A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD","status":"COMPLETED","sponsor":"Graybug Vision","startDate":"2019-09-26","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":56},{"nctId":"NCT02540954","phase":"PHASE3","title":"Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-29","conditions":"Macular Degeneration","enrollment":336},{"nctId":"NCT02949024","phase":"PHASE1, PHASE2","title":"Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Clearside Biomedical, Inc.","startDate":"2016-11-10","conditions":"Diabetic Macular Edema","enrollment":20},{"nctId":"NCT03126786","phase":"PHASE2","title":"Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Clearside Biomedical, Inc.","startDate":"2017-07-11","conditions":"Diabetic Macular Edema","enrollment":71},{"nctId":"NCT04702048","phase":"PHASE4","title":"Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"2021-02-01","conditions":"Retinopathy, Diabetic","enrollment":""},{"nctId":"NCT02980874","phase":"PHASE3","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO","status":"TERMINATED","sponsor":"Clearside Biomedical, Inc.","startDate":"2017-01-31","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":460},{"nctId":"NCT02303184","phase":"PHASE2","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO","status":"COMPLETED","sponsor":"Clearside Biomedical, Inc.","startDate":"2015-01","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":46},{"nctId":"NCT03386474","phase":"PHASE3","title":"Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-01-15","conditions":"Neovascular Age-related Macular Degeneration","enrollment":151},{"nctId":"NCT03085784","phase":"PHASE2","title":"Intravitreal Aflibercept Injection for Radiation Retinopathy Trial","status":"UNKNOWN","sponsor":"Amy C Schefler, MD","startDate":"2017-07-05","conditions":"Radiation Retinopathy","enrollment":40},{"nctId":"NCT02718326","phase":"PHASE3","title":"Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-03-29","conditions":"Nonproliferative Diabetic Retinopathy","enrollment":402},{"nctId":"NCT02800642","phase":"PHASE4","title":"Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-06-10","conditions":"Central Retinal Vein Occlusion","enrollment":162},{"nctId":"NCT03639675","phase":"PHASE3","title":"Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-10-03","conditions":"Glaucoma, Neovascular","enrollment":16},{"nctId":"NCT03521895","phase":"","title":"An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-05-01","conditions":"Macular Degeneration","enrollment":1000},{"nctId":"NCT02495181","phase":"PHASE4","title":"Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2015-11-23","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":50},{"nctId":"NCT03411941","phase":"","title":"Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-28","conditions":"Macular Degeneration","enrollment":116},{"nctId":"NCT02299336","phase":"PHASE4","title":"Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2014-11-24","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT02734407","phase":"PHASE4","title":"Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Retina-Vitreous Associates Medical Group","startDate":"2015-01","conditions":"Clinically Significant Diabetic Macular Edema","enrollment":9},{"nctId":"NCT02297204","phase":"PHASE4","title":"The Endurance 1 Trial","status":"COMPLETED","sponsor":"Northern California Retina Vitreous Associates","startDate":"2014-11","conditions":"Diabetic Macular Edema","enrollment":9},{"nctId":"NCT02581995","phase":"PHASE4","title":"Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-11-19","conditions":"Macular Edema","enrollment":560},{"nctId":"NCT02712008","phase":"PHASE2","title":"Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-03-02","conditions":"Diabetic Macular Edema","enrollment":302},{"nctId":"NCT01578720","phase":"PHASE1","title":"Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome","status":"COMPLETED","sponsor":"Retina Research Institute, LLC","startDate":"2012-06","conditions":"Choroidal Neovascularization, Presumed Ocular Histoplasmosis","enrollment":5},{"nctId":"NCT02396316","phase":"PHASE3","title":"Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-04-02","conditions":"Glaucoma, Neovascular","enrollment":54},{"nctId":"NCT01988662","phase":"PHASE4","title":"UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Neovacular Age-related Macular Degeneration","enrollment":205},{"nctId":"NCT01482910","phase":"PHASE3","title":"VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12","conditions":"Macular Degeneration","enrollment":304},{"nctId":"NCT01796964","phase":"PHASE2","title":"Efficacy and Safety Study of ESBA1008 Versus EYLEA®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-03","conditions":"Exudative Age-Related Macular Degeneration","enrollment":173},{"nctId":"NCT01997164","phase":"PHASE1","title":"Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (\"Wet\") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-11","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":20},{"nctId":"NCT00637377","phase":"PHASE3","title":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Macular Degeneration","enrollment":1240},{"nctId":"NCT00527423","phase":"PHASE2","title":"Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":157},{"nctId":"NCT00943072","phase":"PHASE3","title":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2009-07","conditions":"Macular Edema Secondary to Central Retinal Vein Occlusion","enrollment":189},{"nctId":"NCT00509795","phase":"PHASE3","title":"Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":1217},{"nctId":"NCT00320814","phase":"PHASE1","title":"Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2006-04","conditions":"Diabetic Macular Edema","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":125,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eylea"],"phase":"phase_2","status":"active","brandName":"Aflibercept IVT","genericName":"Aflibercept IVT","companyName":"4D Molecular Therapeutics","companyId":"4d-molecular-therapeutics","modality":"Biologic","firstApprovalDate":"","aiSummary":"Aflibercept IVT is a vascular endothelial growth factor (VEGF) trap that binds and neutralizes VEGF and placental growth factor (PlGF) to inhibit pathological angiogenesis and vascular permeability. Used for Retinal diseases associated with pathological angiogenesis and vascular permeability (e.g., diabetic retinopathy, retinal vein occlusion, age-related macular degeneration).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}